X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.40% | 19.76% | -15.83% | -9,228.01% | 100.71% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -37.18% | -25.42% | 74.36% |
| Total Amortization of Deferred Charges | 11.11% | -6.33% | 4.25% | -5.78% | 11.94% |
| Total Other Non-Cash Items | 6.16% | 13.69% | 515.22% | 94.85% | -295.33% |
| Change in Net Operating Assets | -143.71% | 1,010.56% | 85.60% | -28.29% | -374.25% |
| Cash from Operations | -26.23% | 44.19% | 6.95% | -141.76% | 62.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.26% | 158.77% | -224.04% | 836.52% | 63.43% |
| Cash from Investing | 14.26% | 158.77% | -224.04% | 836.52% | 63.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 68.11% | 1,443.33% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 68.11% | 1,443.33% | -- | -- |
| Foreign Exchange rate Adjustments | -766.67% | 400.00% | -100.72% | 93.06% | 129.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.25% | 384.72% | 3,084.59% | 93.40% | 63.01% |